Accueil   Diary - News   All news TOLLYS

TOLLYS

TOLLYSTOLLYS develops TolX100, an innovative immunotherapy targeting Toll-Like Receptor 3 (TLR3) in the field of cancer.

 

TLR3 ligands are small dsRNA molecules able to specifically induce tumoral cells apoptosis via the Toll-like receptor 3 expressed at the surface of endosomes, without altering normal cells.

Many ligands have already been developed in the past by various scientific teams which showed their clinical efficacy in cancer patients. However, the difficulty to synthetize dsRNA in a reproducible and homogeneic fashion prevented them to be approved by the Health authorities.

With its high accuracy patented synthesis process, the novel dsRNA TOlX100 aims at being the first TLR3 ligand in the cancer market. TolX100 is a dsRNA Poly C: Poly (G/I) of exactly 100bp, synthetized by an enzyme able to produce a complementary ssRNA from a simple strand template RNA in a very reproducible way, answering for the first time to the regulatory authorities requirements.

TOLLYS has already brought the proof of concept of the efficacy of the molecule in vitro and in models of chicken embryos and mice.

In order to select patients the most likely to respond to the treatment with TolX100, TOLLYS will develop a companion test, based on a monoclonal antibody recognizing TLR3 in endosomes of tumoral cells.

90% of tumors are epithelial ones. TOLLYS estimates that approximately 40% of them express TLR3. Therapeutic potential of TolX100 is thus considerable.

In 2012, there were 14.1 million cases of cancers. TolX100 could represent a hope for almost 5 million patients.

The co-founders want to conduct the development of the molecule until phase I/IIa included and sell the company to a big pharma.

 

About TOLLYS

 

TOLLYS has been created on July, 2nd 2015 by 5 co-founders: 2 researchers from the Centre de Recherche en Cancérologie de Lyon, the Pr Serge Lebecque and the Dr Toufic Renno, both of them having more than 20 years of experience in the field of TLR3 in cancerology, the Dr Dominique Rigal, former president of EFS-Lyon, Philippe Guillot-Chêne, former president of Humalys, and Jacques-François Martin, former CEO of Institut Mérieux.

The Centre Léon Bérard has already joined the group of founders by investing for the second time of its history in a start-up.

 

TOLLYS website is still under construction

 

 

 

By continuing to browse our site you agree to our use of cookies, revised Privacy Policy and Terms of Service. More information... Close